Evidence of d-phenylglycine as delivering tool for improving l-dopa absorption

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Wang, Chun Li ^a   Fan, Yang Bin ^a   Lu, Hsiao Hwa ^b   Tsai, Tung Hu ^c   Tsai, Ming Cheng ^d   Wang, Hui Po ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Roche Products Ltd   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO PHENYLGLYCINE LEVO DOPA; LEVODOPA; PEPTIDE TRANSPORTER 1; PHENYLGLYCINE; PRODRUG; UNCLASSIFIED DRUG; 2 PHENYLGLYCINE; 2-PHENYLGLYCINE; COTRANSPORTER; DOPAMINE; DRUG CARRIER; DRUG DERIVATIVE; GLYCINE; SLC15A1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN MICRODIALYSIS; BRUSH BOARDER MEMBRANE VESICLE; COMPARATIVE STUDY; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STABILITY; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; INTESTINE PERFUSION; MALE; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MEMBRANE VESICLE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOAVAILABILITY; HUMAN; METABOLISM; MICROVILLUS; PARKINSON DISEASE; PHYSIOLOGY; ROTAROD TEST; TRANSPORT VESICLE; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DRUG CARRIERS; GLYCINE; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; MICRODIALYSIS; MICROVILLI; PARKINSON DISEASE; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SYMPORTERS; TRANSPORT VESICLES;

EID: 78049400764     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-71     Document Type: Article

References (37)

1. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in Parkinsonism. Birkmayer W, Hornykiewicz O, Parkinsonism Relat Disord 1998 4 59 60 10.1016/S1353-8020(98)00013-3 18591089 (Pubitemid 28525350)
2. Levodopa: Past, present and future. Hauser R, Eur Neurol 2009 62 1 8 10.1159/000215875 19407449
3. Levodopa for the treatment of Parkinson's disease. LeWitt PA, N Eng J Med 2008 359 2468 2476 10.1056/NEJMct0800326
4. The scientific and clinical basis for the treatment of Parkinson's disease. Olanow CW, Stern MB, Sethi K, Neurology 2009 72 Suppl 4 1 S136 10.1212/WNL.0b013e3181a1d44c 19470958
5. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Juncos JL, Neurol Clin 1992 10 487 509 1584186
6. Inter- and intra-individual variation in l-dopa pharmacokinetics in the treatment of Parkinson's disease. Nomoto M, Nishikawa N, Nagai M, Yabe H, Nakatsuka A, Moritoyo H, Moritoyo T, Kubo M, Parkinsonism Relat Disord 2009 15 Suppl 1 21 S24 10.1016/S1353-8020(09)70007-0 19131037
7. Molecular mechanisms of l-dopa -induced dyskinesia. Jenner P, Nat Rev Neurosci 2008 9 665 677 10.1038/nrn2471 18714325
8. Optimising levodopa therapy. Abbruzzese G, Neurol Sci 2008 29 377 S379 10.1007/s10072-008-1051-x 19381767
9. The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK, Br J Clin Pharmacol 1993 35 243 250 8471400 (Pubitemid 23074047)
10. Dietary factors in the management of Parkinson's Disease. Kempster PA, Wahlqvist ML, Nutr Rev 1994 52 51 58 8183469 (Pubitemid 24090161)
11. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Crevoisier C, Zerr P, Calvi-Gries F, Nilsen T, Eur J Pharm Biopharm 2003 55 71 76 10.1016/S0939-6411(02)00124-8 12551706 (Pubitemid 36120497)
12. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Groneberg DA, Döring F, Eynott PR, Fischer A, Daniel H, Am J Physiol Gastrointest Liver Physiol 2001 281 697 G704 11518682
13. Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1. Brodin B, Nielsen CU, Steffansen B, Frokjaer S, Pharmacol Toxicol 2002 90 285 296 10.1034/j.1600-0773.2002.900601.x 12403049 (Pubitemid 34713193)
14. Quantitative evaluation of PEPT1 contribution to oral absorption of cephalexin in rats. Hironaka T, Itokawa S, Ogawara K, Higaki K, Kimura T, Pharm Res 2009 26 40 50 10.1007/s11095-008-9703-3 18784906
15. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M, J Pharmacol Exp Ther 2008 327 432 41 10.1124/jpet.108.143339 18713951
16. The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Brandsch M, Knutter L, Leibach FH, Eur J Pharm Sci 2004 21 53 60 10.1016/S0928-0987(03)00142-8 14706811 (Pubitemid 38050203)
17. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. Vig BS, Stouch TR, Timoszyk JK, Quan Y, Wall DA, Smith RL, Faria TN, J Med Chem 2006 49 3636 3644 10.1021/jm0511029 16759105 (Pubitemid 43902468)
18. +/peptide symporter, hPEPT1: Affinity prediction using alignment-independent descriptors. Larsen SB, Jørgensen FS, Olsen L, J Chem Inf Model 2008 48 233 241 10.1021/ci700346y 18092768 (Pubitemid 351271069)
19. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Brandsh M, Expert Opin Drug Metab Toxicol 2009 5 887 905 10.1517/17425250903042292 19519280
20. Membrane transporter/receptor-targeted prodrug design: Strategies for human and veterinary drug development. Majumdar S, Duvvuri S, Mitra AK, Adv Drug Deliv Rev 2004 56 1437 1452 10.1016/j.addr.2004.02.006 15191791 (Pubitemid 38748825)
21. Intestinal absorption studies on peptide mimetic alpha-methyldopa prodrugs. Wang HP, Lu HH, Lee JS, Cheng CY, Mah JR, Hsu WL, Yen CF, Lin CJ, Kuo HS, J Pharm Pharmacol 1996 48 270 276 8737052 (Pubitemid 26159142)
22. Biological Transporters as Target for New Drug Design. Wang HP, Wang CL, J Exp Clin Med 2010 1 31 38 10.1016/S1878-3317(09)60008-5
23. Preparation and use of renal and intestinal plasma membrane vesicles for toxicological studies. Sheikh MI, Muller JV, Biochemical Toxicology: A Practical Approach IRL press, Oxford, Snell K, Mullock B, 1 1987 153 182
24. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. Anand BS, Patel J, Mitra AK, J Pharmacol Exp Ther 2003 304 781 791 10.1124/jpet.102.044313 12538834 (Pubitemid 36152357)
25. + gradient-dependent transport of aminocephalosporins in rat intestinal brush-border membrane vesicles. Okano T, Inui K, Takano M, Hori R, Biochem Pharmacol 1986 35 1781 1786 10.1016/0006-2952(86)90292-3 3718527 (Pubitemid 16046199)
26. Influence of d-glucose-induced water absorption on rat jejunal uptake of two passively absorbed drugs. Lu HH, Thomas J, Fleisher D, J Pharm Sci 1992 81 21 25 10.1002/jps.2600810105 1619565
27. Use of the peptide carrier system to improve the intestinal absorption of l-alpha-methyldopa: Carrier kinetics, intestinal permeabilities and in vitro hydrolysis of dipeptidyl derivatives of l-alpha-methyldopa. Hu M, Subramanian P, Mosberg HI, Amidon GL, Pharm Res 1989 6 66 70 10.1023/A:1015855820488 2717522 (Pubitemid 19060826)
28. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Amidon GL, Sinko PJ, Fleisher D, Pharm Res 1988 5 651 654 10.1023/A: 1015927004752 3244618 (Pubitemid 18263612)
29. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. Reigelman S, Collier P, J Pharmacokinet Biopharm 1980 8 509 534 10.1007/BF01059549 7252794 (Pubitemid 11136588)
30. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug. Kaplan SA, Jack ML, Cotler S, Alexander K, J Pharmacokinet Pharmacodyn 1973 1 201 216
31. Paxinos G, Waston C, The Rat Brain in Sterotaxic Coordinates New York: Academic Press 2 1986
32. Correlation of apomorphine and amphetamine induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhard GA, Brain Res 1993 626 167 174 10.1016/0006-8993(93)90576-9 8281427 (Pubitemid 23306825)
33. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Iancu R, Mohapel P, Brundin P, Paul G, Behav Brain Res 2005 162 1 10 10.1016/j.bbr.2005.02.023 15922062 (Pubitemid 40726275)
34. Experimental models of Parkinson's disease. Beal MF, Nat Rev Neurosci 2001 2 325 332 10.1038/35072550 11331916 (Pubitemid 33680574)
35. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis. Metz GA, Tse A, Ballermann M, Smith LK, Fouad K, Eur J Neurosci 2005 22 735 744 10.1111/j.1460-9568.2005.04238.x 16101755 (Pubitemid 41192283)
36. Animal data: The contribution of the Ussing chamber and perfusion system to predicting human oral drug delivery in vivo. Lennernäs H, Adv Drug Deliv Rev 2007 59 1103 1120 10.1016/j.addr.2007.06.016 17900749 (Pubitemid 47615203)
37. Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. Johnson DA, Amidon GL, J Theor Biol 1988 131 93 106 10.1016/S0022-5193(88)80123-1 3419195